바이러스 벡터 제조 시장 : 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Persistence Market Research has conducted a thorough analysis of the Viral Vector Manufacturing Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Viral Vector Manufacturing Market spanning from 2024 to 2032.

The global revenue from viral vector manufacturing hit $624.7 million in 2024, and the market is expected to grow at a compound annual growth rate (CAGR) of 18.7%. By 2032, it's projected to reach a valuation of $3.46 billion.

Key Insights:

• Viral Vector Manufacturing Market Size (2024): $624.7 million
• Projected Market Value (2032): $3.46 billion
• Global Market Growth Rate (CAGR 2024-2032): 18.7%.

Viral Vector Manufacturing Market - Report Scope:

Viral vectors play a pivotal role in various fields, including gene therapy, vaccine development, and molecular biology research. These vectors are engineered viruses that can deliver genetic material into target cells, facilitating the expression of therapeutic genes or antigens. The Viral Vector Manufacturing market serves pharmaceutical companies, biotechnology firms, research institutions, and contract manufacturing organizations (CMOs), offering a range of viral vector production services, including adeno-associated viruses (AAVs), lentiviruses, adenoviruses, and retroviruses. Market growth is fueled by the growing demand for gene therapy and vaccine candidates targeting a wide range of genetic disorders, infectious diseases, and cancers. Additionally, advancements in viral vector design, manufacturing technologies, and regulatory frameworks further accelerate market expansion.

Market Growth Drivers:

The global Viral Vector Manufacturing market is propelled by several factors, including the increasing adoption of gene therapy for the treatment of rare genetic diseases, such as spinal muscular atrophy (SMA) and hemophilia, as well as cancer immunotherapy. The rising investment in research and development (R&D) activities by pharmaceutical companies and academic institutions to develop novel gene therapies and vaccines drives market demand for viral vector manufacturing services. Moreover, the emergence of innovative viral vector platforms, such as self-inactivating lentiviral vectors and next-generation AAV vectors, enhances transduction efficiency, safety, and scalability, fostering market growth.

Market Restraints:

Despite promising growth prospects, the Viral Vector Manufacturing market faces challenges related to manufacturing scalability, product quality, and regulatory compliance. The complex nature of viral vector production, including cell culture processes, purification techniques, and quality control assays, poses technical and logistical hurdles for manufacturers, affecting production yields and timelines. Furthermore, stringent regulatory requirements governing the manufacturing, testing, and distribution of viral vectors, particularly in gene therapy applications, impose compliance burdens and increase operational costs for market players. Addressing these challenges necessitates investments in process optimization, automation, and analytical technologies to ensure product consistency, safety, and regulatory compliance.

Market Opportunities:

The Viral Vector Manufacturing market presents significant growth opportunities driven by technological innovations, therapeutic advancements, and strategic collaborations. The development of novel viral vector platforms, such as synthetic AAVs and modified adenoviruses, expands the application scope of gene therapy and vaccine development, addressing unmet medical needs and diversifying revenue streams for manufacturers. Furthermore, the integration of advanced manufacturing technologies, such as single-use bioreactors, continuous manufacturing, and gene editing tools, enhances production efficiency, flexibility, and cost-effectiveness, enabling rapid scale-up and commercialization of viral vector-based products. Strategic partnerships, licensing agreements, and acquisitions facilitate technology transfer, capacity expansion, and market penetration, positioning companies for long-term success in the evolving Viral Vector Manufacturing landscape.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Viral Vector Manufacturing market globally?
• Which viral vector platforms and therapeutic applications are driving market demand across different industry segments?
• How are technological advancements reshaping the competitive landscape of the Viral Vector Manufacturing market?
• Who are the key players contributing to the Viral Vector Manufacturing market, and what strategies are they employing to maintain market leadership?
• What are the emerging trends and future prospects in the global Viral Vector Manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global Viral Vector Manufacturing market, including Lonza Group AG, Thermo Fisher Scientific Inc., and Cobra Biologics Ltd., focus on innovation, process optimization, and strategic partnerships to gain a competitive advantage. These companies invest in R&D to develop advanced viral vector production platforms, including suspension cell culture systems, transient transfection technologies, and downstream purification methods, meeting the growing demand for scalable and cost-effective manufacturing solutions. Collaborations with biopharmaceutical companies, academic research centers, and regulatory agencies facilitate technology transfer, process validation, and regulatory approval, expediting market entry and product commercialization. Moreover, emphasis on quality management, compliance with Good Manufacturing Practice (GMP) standards, and continuous improvement initiatives ensures product quality, safety, and regulatory compliance, fostering customer trust and brand reputation in the dynamic Viral Vector Manufacturing landscape.

Key Companies Profiled

• Thermo Fisher Scientific Inc
• Charles River
• (Cobra Biologics)
• NOVASEP
• uniQure N.V
• Waisman Biomanufacturing
• Creative Biogene
• GenScript Biotech Corporation
• Novartis AG
• Merck KGaA
• Takara Bio, Inc.
• FUJIFILM Diosynth Biotechnologies
• LONZA
• Danaher Corp. (Aldevron)
• Sirion Biotech GmbH
• AGC Biologics

Key Segments of Manufacturing of Viral Vector Industry Research

By Virus Type:

• Lentiviral Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retrovirus

By Expression System:

• Transient
• Stable

By Application:

• Gene Therapy
• Vaccines
• Cancer Therapy
• Others

By End User:

• Biotechnology Companies
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Inclusions

• 4.1. Product Adoption Analysis
• 4.2. Regulatory Scenario
• 4.3. PESTEL analysis
• 4.4. Porter's Analysis
• 4.5. Key Promotional and Branding Strategies, By Manufacturers
• 4.6. Value Chain Analysis

5. COVID-19 Crisis Analysis

• 5.1. 2024 Market Scenario
• 5.2. COVID-19 and Impact Analysis
  • 5.2.1. By Virus Type
  • 5.2.2. By Expression System
  • 5.2.3. By Application
  • 5.2.4. By End User
  • 5.2.5. By Region

6. Market Background

• 6.1. Macro-Economic Factors
  • 6.1.1. Global GDP Growth Outlook
  • 6.1.2. Global Healthcare Expenditure Outlook
  • 6.1.3. Gloal Gene Therapy Market Outlook
• 6.2. Forecast Factors - Relevance & Impact
  • 6.2.1. Increasing drug discovery
  • 6.2.2. Rapid growth in the biotechnology and biopharmaceutical industries
  • 6.2.3. Increasing R&D Research in Genetics and Viral Technology
  • 6.2.4. Increasing Adoption of Gene therapy
  • 6.2.5. Increasing R&D in vaccine development
• 6.3. Market Dynamics
  • 6.3.1. Drivers
  • 6.3.2. Restraints
  • 6.3.3. Opportunity Analysis

7. Global Viral Vector Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Virus Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis, By Virus Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Virus Type, 2024-2032
  • 8.3.1. Lentiviral Vectors
  • 8.3.2. Adenoviral Vectors
  • 8.3.3. Adeno-associated viral vectors (AAV)
  • 8.3.4. Retrovirus
• 8.4. Market Attractiveness Analysis By Virus Type

9. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Expression System

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Expression System, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Expression System, 2024-2032
  • 9.3.1. Transient
  • 9.3.2. Stable
• 9.4. Market Attractiveness Analysis By Expression System

10. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Application

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2032
  • 10.3.1. Gene Therapy
  • 10.3.2. Vaccines
  • 10.3.3. Cancer Therapy
  • 10.3.4. Others
• 10.4. Market Attractiveness Analysis By Application

11. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By End User

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2032
  • 11.3.1. Biopharmaceutical Companies
  • 11.3.2. Academic & Research Institutes
  • 11.3.3. Contract Research Organizations
  • 11.3.4. Contract Manufacturing Organizations
• 11.4. Market Attractiveness Analysis By End User

12. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East & Africa
• 12.4. Market Attractiveness Analysis By Region

13. North America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Virus Type
  • 13.3.3. By Expression System
  • 13.3.4. By Application
  • 13.3.5. By End User
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Virus Type
  • 13.4.3. By Expression System
  • 13.4.4. By Application
  • 13.4.5. By End User
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Viral Vector Manufacturing Market
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Virus Type
      • 13.8.1.2.2. By Expression System
      • 13.8.1.2.3. By Application
      • 13.8.1.2.4. By End User
  • 13.8.2. Canada Viral Vector Manufacturing Market
  • 13.8.3. Introduction
  • 13.8.4. Market Analysis and Forecast by Market Taxonomy
    • 13.8.4.1. By Virus Type
    • 13.8.4.2. By Expression System
    • 13.8.4.3. By Application
    • 13.8.4.4. By End User

14. Latin America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Virus Type
  • 14.3.3. By Expression System
  • 14.3.4. By Application
  • 14.3.5. By End User
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Virus Type
  • 14.4.3. By Expression System
  • 14.4.4. By Application
  • 14.4.5. By End User
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Viral Vector Manufacturing Market
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Virus Type
      • 14.8.1.2.2. By Expression System
      • 14.8.1.2.3. By Application
      • 14.8.1.2.4. By End User
  • 14.8.2. Mexico Viral Vector Manufacturing Market
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Virus Type
      • 14.8.2.2.2. By Expression System
      • 14.8.2.2.3. By Application
      • 14.8.2.2.4. By End User
  • 14.8.3. Argentina Viral Vector Manufacturing Market
  • 14.8.4. Introduction
  • 14.8.5. Market Analysis and Forecast by Market Taxonomy
    • 14.8.5.1. By Virus Type
    • 14.8.5.2. By Expression System
    • 14.8.5.3. By Application
    • 14.8.5.4. By End User

15. Europe Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. U.K.
    • 15.3.1.2. Germany
    • 15.3.1.3. Italy
    • 15.3.1.4. France
    • 15.3.1.5. Spain
    • 15.3.1.6. Russia
    • 15.3.1.7. Nordic Countries
    • 15.3.1.8. BENELUX
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Virus Type
  • 15.3.3. By Expression System
  • 15.3.4. By Application
  • 15.3.5. By End User
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Virus Type
  • 15.4.3. By Expression System
  • 15.4.4. By Application
  • 15.4.5. By End User
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. U.K. Viral Vector Manufacturing Market
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Virus Type
      • 15.8.1.2.2. By Expression System
      • 15.8.1.2.3. By Application
      • 15.8.1.2.4. By End User
  • 15.8.2. Germany Viral Vector Manufacturing Market
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Virus Type
      • 15.8.2.2.2. By Expression System
      • 15.8.2.2.3. By Application
      • 15.8.2.2.4. By End User
  • 15.8.3. Italy Viral Vector Manufacturing Market
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Virus Type
      • 15.8.3.2.2. By Expression System
      • 15.8.3.2.3. By Application
      • 15.8.3.2.4. By End User
  • 15.8.4. France Viral Vector Manufacturing Market
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Virus Type
      • 15.8.4.2.2. By Expression System
      • 15.8.4.2.3. By Application
      • 15.8.4.2.4. By End User
  • 15.8.5. Spain Viral Vector Manufacturing Market
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Virus Type
      • 15.8.5.2.2. By Expression System
      • 15.8.5.2.3. By Application
      • 15.8.5.2.4. By End User
  • 15.8.6. Russia Viral Vector Manufacturing Market
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Virus Type
      • 15.8.6.2.2. By Expression System
      • 15.8.6.2.3. By Application
      • 15.8.6.2.4. By End User
  • 15.8.7. Nordic Countries Viral Vector Manufacturing Market
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Virus Type
      • 15.8.7.2.2. By Expression System
      • 15.8.7.2.3. By Application
      • 15.8.7.2.4. By End User
  • 15.8.8. BENELUX Viral Vector Manufacturing Market
    • 15.8.8.1. Introduction
    • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.8.2.1. By Virus Type
      • 15.8.8.2.2. By Expression System
      • 15.8.8.2.3. By Application
      • 15.8.8.2.4. By End User

16. South Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Philippines
    • 16.3.1.5. Thailand
    • 16.3.1.6. Vietnam
    • 16.3.1.7. Rest of South Asia
  • 16.3.2. By Virus Type
  • 16.3.3. By Expression System
  • 16.3.4. By Application
  • 16.3.5. By End User
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Virus Type
  • 16.4.3. By Expression System
  • 16.4.4. By Application
  • 16.4.5. By End User
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Viral Vector Manufacturing Market
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Virus Type
      • 16.8.1.2.2. By Expression System
      • 16.8.1.2.3. By Application
      • 16.8.1.2.4. By End User
  • 16.8.2. Indonesia Viral Vector Manufacturing Market
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Virus Type
      • 16.8.2.2.2. By Expression System
      • 16.8.2.2.3. By Application
      • 16.8.2.2.4. By End User
  • 16.8.3. Malaysia Viral Vector Manufacturing Market
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Virus Type
      • 16.8.3.2.2. By Expression System
      • 16.8.3.2.3. By Application
      • 16.8.3.2.4. By End User
  • 16.8.4. Philippines Viral Vector Manufacturing Market
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Virus Type
      • 16.8.4.2.2. By Expression System
      • 16.8.4.2.3. By Application
      • 16.8.4.2.4. By End User
  • 16.8.5. Thailand Viral Vector Manufacturing Market
    • 16.8.5.1. Introduction
    • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.5.2.1. By Virus Type
      • 16.8.5.2.2. By Expression System
      • 16.8.5.2.3. By Application
      • 16.8.5.2.4. By End User
  • 16.8.6. Vietnam Viral Vector Manufacturing Market
    • 16.8.6.1. Introduction
    • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.6.2.1. By Virus Type
      • 16.8.6.2.2. By Expression System
      • 16.8.6.2.3. By Application
      • 16.8.6.2.4. By End User

17. East Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Virus Type
  • 17.3.3. By Expression System
  • 17.3.4. By Application
  • 17.3.5. By End User
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Virus Type
  • 17.4.3. By Expression System
  • 17.4.4. By Application
  • 17.4.5. By End User
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China Viral Vector Manufacturing Market
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Virus Type
      • 17.8.1.2.2. By Expression System
      • 17.8.1.2.3. By Application
      • 17.8.1.2.4. By End User
  • 17.8.2. Japan Viral Vector Manufacturing Market
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Virus Type
      • 17.8.2.2.2. By Expression System
      • 17.8.2.2.3. By Application
      • 17.8.2.2.4. By End User
  • 17.8.3. South Korea Viral Vector Manufacturing Market
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Virus Type
      • 17.8.3.2.2. By Expression System
      • 17.8.3.2.3. By Application
      • 17.8.3.2.4. By End User

18. Oceania Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Virus Type
  • 18.3.3. By Expression System
  • 18.3.4. By Application
  • 18.3.5. By End User
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Virus Type
  • 18.4.3. By Expression System
  • 18.4.4. By Application
  • 18.4.5. By End User
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Viral Vector Manufacturing Market
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Virus Type
      • 18.8.1.2.2. By Expression System
      • 18.8.1.2.3. By Application
      • 18.8.1.2.4. By End User
  • 18.8.2. New Zealand Viral Vector Manufacturing Market
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Virus Type
      • 18.8.2.2.2. By Expression System
      • 18.8.2.2.3. By Application
      • 18.8.2.2.4. By End User

19. Middle East and Africa Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. Israel
    • 19.3.1.4. Northern Africa
    • 19.3.1.5. South Africa
    • 19.3.1.6. Rest of Middle East and Africa
  • 19.3.2. By Virus Type
  • 19.3.3. By Expression System
  • 19.3.4. By Application
  • 19.3.5. By End User
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Virus Type
  • 19.4.3. By Expression System
  • 19.4.4. By Application
  • 19.4.5. By End User
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Viral Vector Manufacturing Market
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Virus Type
      • 19.8.1.2.2. By Expression System
      • 19.8.1.2.3. By Application
      • 19.8.1.2.4. By End User
  • 19.8.2. Turkey Viral Vector Manufacturing Market
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Virus Type
      • 19.8.2.2.2. By Expression System
      • 19.8.2.2.3. By Application
      • 19.8.2.2.4. By End User
  • 19.8.3. Israel Viral Vector Manufacturing Market
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Virus Type
      • 19.8.3.2.2. By Expression System
      • 19.8.3.2.3. By Application
      • 19.8.3.2.4. By End User
  • 19.8.4. South Africa Viral Vector Manufacturing Market
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Virus Type
      • 19.8.4.2.2. By Expression System
      • 19.8.4.2.3. By Application
      • 19.8.4.2.4. By End User
  • 19.8.5. North Africa Viral Vector Manufacturing Market
    • 19.8.5.1. Introduction
    • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.5.2.1. By Virus Type
      • 19.8.5.2.2. By Expression System
      • 19.8.5.2.3. By Application
      • 19.8.5.2.4. By End User

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. Regional Footprint of Players
  • 20.3.2. Product Foot Print by Players
  • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Thermo Fisher Scientific Inc
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Sales Footprint
    • 21.3.1.4. Key Financials
    • 21.3.1.5. SWOT Analysis
    • 21.3.1.6. Strategy Overview
      • 21.3.1.6.1. Marketing Strategy
      • 21.3.1.6.2. Product Strategy
      • 21.3.1.6.3. Channel Strategy
  • 21.3.2. Charles River (Cobra Biologics)
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Sales Footprint
    • 21.3.2.4. Key Financials
    • 21.3.2.5. SWOT Analysis
    • 21.3.2.6. Strategy Overview
      • 21.3.2.6.1. Marketing Strategy
      • 21.3.2.6.2. Product Strategy
      • 21.3.2.6.3. Channel Strategy
  • 21.3.3. Novasep
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Sales Footprint
    • 21.3.3.4. Key Financials
    • 21.3.3.5. SWOT Analysis
    • 21.3.3.6. Strategy Overview
      • 21.3.3.6.1. Marketing Strategy
      • 21.3.3.6.2. Product Strategy
      • 21.3.3.6.3. Channel Strategy
  • 21.3.4. uniQure N.V.
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Sales Footprint
    • 21.3.4.4. Key Financials
    • 21.3.4.5. SWOT Analysis
    • 21.3.4.6. Strategy Overview
      • 21.3.4.6.1. Marketing Strategy
      • 21.3.4.6.2. Product Strategy
      • 21.3.4.6.3. Channel Strategy
  • 21.3.5. Waisman Biomanufacturing
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Sales Footprint
    • 21.3.5.4. Key Financials
    • 21.3.5.5. SWOT Analysis
    • 21.3.5.6. Strategy Overview
      • 21.3.5.6.1. Marketing Strategy
      • 21.3.5.6.2. Product Strategy
      • 21.3.5.6.3. Channel Strategy
  • 21.3.6. Creative Biogene
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Sales Footprint
    • 21.3.6.4. Key Financials
    • 21.3.6.5. SWOT Analysis
    • 21.3.6.6. Strategy Overview
      • 21.3.6.6.1. Marketing Strategy
      • 21.3.6.6.2. Product Strategy
      • 21.3.6.6.3. Channel Strategy
  • 21.3.7. GenScript Biotech Corporation
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Sales Footprint
    • 21.3.7.4. Key Financials
    • 21.3.7.5. SWOT Analysis
    • 21.3.7.6. Strategy Overview
      • 21.3.7.6.1. Marketing Strategy
      • 21.3.7.6.2. Product Strategy
      • 21.3.7.6.3. Channel Strategy
  • 21.3.8. Novartis AG
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Sales Footprint
    • 21.3.8.4. Key Financials
    • 21.3.8.5. SWOT Analysis
    • 21.3.8.6. Strategy Overview
      • 21.3.8.6.1. Marketing Strategy
      • 21.3.8.6.2. Product Strategy
      • 21.3.8.6.3. Channel Strategy
  • 21.3.9. Merck KGaA.
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Sales Footprint
    • 21.3.9.4. Key Financials
    • 21.3.9.5. SWOT Analysis
    • 21.3.9.6. Strategy Overview
      • 21.3.9.6.1. Marketing Strategy
      • 21.3.9.6.2. Product Strategy
      • 21.3.9.6.3. Channel Strategy
  • 21.3.10. Takara Bio Inc.
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Sales Footprint
    • 21.3.10.4. Key Financials
    • 21.3.10.5. SWOT Analysis
    • 21.3.10.6. Strategy Overview
      • 21.3.10.6.1. Marketing Strategy
      • 21.3.10.6.2. Product Strategy
      • 21.3.10.6.3. Channel Strategy
  • 21.3.11. FUJIFILM Diosynth Biotechnologies
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Sales Footprint
    • 21.3.11.4. Key Financials
    • 21.3.11.5. SWOT Analysis
    • 21.3.11.6. Strategy Overview
      • 21.3.11.6.1. Marketing Strategy
      • 21.3.11.6.2. Product Strategy
      • 21.3.11.6.3. Channel Strategy
  • 21.3.12. Lonza
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Sales Footprint
    • 21.3.12.4. Key Financials
    • 21.3.12.5. SWOT Analysis
    • 21.3.12.6. Strategy Overview
      • 21.3.12.6.1. Marketing Strategy
      • 21.3.12.6.2. Product Strategy
      • 21.3.12.6.3. Channel Strategy
  • 21.3.13. Danaher Corp. (Aldevron)
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Sales Footprint
    • 21.3.13.4. Key Financials
    • 21.3.13.5. SWOT Analysis
    • 21.3.13.6. Strategy Overview
      • 21.3.13.6.1. Marketing Strategy
      • 21.3.13.6.2. Product Strategy
      • 21.3.13.6.3. Channel Strategy
  • 21.3.14. Sirion-Biotech GmbH
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Sales Footprint
    • 21.3.14.4. Key Financials
    • 21.3.14.5. SWOT Analysis
    • 21.3.14.6. Strategy Overview
      • 21.3.14.6.1. Marketing Strategy
      • 21.3.14.6.2. Product Strategy
      • 21.3.14.6.3. Channel Strategy
  • 21.3.15. AGC Biologics
    • 21.3.15.1. Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Sales Footprint
    • 21.3.15.4. Key Financials
    • 21.3.15.5. SWOT Analysis
    • 21.3.15.6. Strategy Overview
      • 21.3.15.6.1. Marketing Strategy
      • 21.3.15.6.2. Product Strategy
      • 21.3.15.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology